New protease inhibitors and non-nucleoside reverse transcriptase inhibitors.
Lascar
Monica
M
Mortimer Market Centre, London, UK. monix@doctors.net.uk
Cartledge
Jonathan D
JD
D002986:Clinical Trials as Topic; D000069454:Darunavir; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D006678:HIV / Q000187:drug effects / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009570:Nitriles; D011724:Pyridazines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines; D011753:Pyrones / Q000494:pharmacology / Q000627:therapeutic use*; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D017320:HIV Protease Inhibitors; D009570:Nitriles; D011724:Pyridazines; D011725:Pyridines; D011743:Pyrimidines; D011753:Pyrones; D013449:Sulfonamides; C451734:etravirine; D000069454:Darunavir; C107201:tipranavir